Navigation Links
Clinilabs Sponsors The ADA's 2013 Step Out: Walk to Stop Diabetes

NEW YORK, Sept. 5, 2013 /PRNewswire-iReach/ -- Clinilabs, a contract research organization that provides early-phase and specialty clinical drug development services to industry, announced today that they will sponsor the American Diabetes Association's (ADA) Step Out: Walk to Stop Diabetes this September.  The event is held every year in an effort to raise money for Diabetes awareness. 

Diabetes is a serious illness that affects roughly 10% of the population.  The disease can cause several complications, including stroke and heart attack, which result in over 200,000 diabetes related deaths a year.  As a leading specialty contract research organization (CRO), Clinilabs understands the impact of the high prevalence of diabetes in our country, and is determined to help the American Diabetes Association (ADA) support research that will lead to better treatments for this disease. Lead Recruiter, Carrie Sorkin, acknowledges the importance of taking part in Step Out by stating "as an organization that is heavily involved in clinical care and drug development, we see first-hand the effect that diabetes has on our patients.  Because of this, we feel that it is our responsibility to do our best to raise awareness about the health implications of this terrible disease."

The Step Out: Walk to Stop Diabetes event is conducted every year in over 125 locations nationwide.  For over 20 years the ADA, along with thousands of volunteers, has helped raise over $175 million for Diabetes research.  This year, over 120,000 participants, along with the Clinilabs team, are expected to raise $2 million in New York State events alone. 

Clinilabs will sponsor three of the New York walks, taking place in Manhattan, Yonkers, and Long Island on September 28th and 29th. Walkers can visit the Clinilabs booth for free prizes, educational materials, clinical consultations, and information on participating in clinical trials for diabetes. All walkers who visit the Clinilabs booth will have a chance to win a ZEKI tablet.  If you or anyone you know is interested in participating or would like to learn more about Diabetes, visit the American Diabetes Association's website at

About Clinilabs Inc.

Clinilabs is a full-service contract research organization (CRO) that specializes in early-phase studies, from first-in-human to proof-of-concept, with normal healthy volunteers and patient populations.  The company owns and operates two Phase I units in the US, and maintains a network of highly qualified investigator sites for multicenter Phase II studies Worldwide.  Specialty projects, including pharmacodynamic, biomarker, cardiac safety, sleep/wakefulness, Diabetes/metabolic and Japanese bridging are among our strengths.  Clinilabs is recognized globally as a leading specialty CRO, offering an alternative to large CROs for specialty projects.  For more information, please visit

Media Contact: Hannah DAoust, Clinilabs, 646-215-6480,

News distributed by PR Newswire iReach:

SOURCE Clinilabs
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinilabs Launches Research Volunteer Authentication Initiative
2. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
3. PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
4. Houston Bulk Materials Handling Society Sponsors Texas Powder & Bulk Solids Expo
5. Cash Store Sponsors The WALK At The Detroit Zoo
6. Millennium Research Group Sponsors Case Competition at Western University for Second Year
7. Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project
8. ERISA Creates Benchmarking Challenges for Plan Sponsors
9. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
10. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
11. Easy on the Stomach: ALCAT Worldwide Sponsors Successful Conference on Gut, Brain & Autoimmune Disorders
Post Your Comments:
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
Breaking Medicine News(10 mins):